Addex Therapeutics LTD. 6-K Filing
Ticker: ADXN · Form: 6-K · Filed: Dec 4, 2025 · CIK: 1574232
Sentiment: neutral
Filing Stats: 401 words · 2 min read · ~1 pages · Grade level 12.7 · Accepted 2025-12-04 06:00:31
Filing Documents
- tm2532672d1_6k.htm (6-K) — 17KB
- tm2532672d1_ex99-1.htm (EX-99.1) — 903KB
- tm2532672d1_ex99-2.htm (EX-99.2) — 198KB
- tm2532672d1_ex99-3.htm (EX-99.3) — 52KB
- tm2532672d1_ex99-3img001.jpg (GRAPHIC) — 11KB
- 0001104659-25-118226.txt ( ) — 1186KB
RISK FACTORS
RISK FACTORS Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form 6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission on May 15, 2025. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking as a result of certain factors including the risks described in our Annual Report and our other SEC filings. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd By: /s/ Tim Dyer Name: Tim Dyer Date: December 4, 2025 Title: Chief Executive Officer 3 EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 : Unaudited interim Condensed Consolidated Financial Statements Exhibit 99.2 : Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.3 : Press Release dated December 4, 2025 4